Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
ONLS
АТХ:A.05.B.A Preparations for the treatment of liver diseases
Pharmacodynamics:Combined means.
Glycyrrhizic acid
Stimulates the production of interferon and enhances the reaction of phagocytosis, due to which suppresses the reproduction of viruses. It has antioxidant and membrane stabilizing activity. Strengthens the action of endogenous glucocorticoids, providing anti-inflammatory and antiallergic effects.
Phosphatidylcholine
It is an active component of phospholipids. As a structural element of the cell membrane has a cytoprotective effect. Normalizes lipid and protein metabolism in hepatocytes, prevents the formation of connective tissue, preventing the development of fibrosis and cirrhosis of the liver.
Pharmacokinetics:Glycyrrhizic acid
After oral administration in the gastrointestinal tract, it is metabolized to β-glyceric acid. The maximum concentration in the blood plasma is reached after 2 hours.The connection with plasma proteins is 90%.
The half-life is 5-8 hours. Elimination with bile.
Phosphatidylcholine
After oral administration, up to 90% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved in 1-2 hours.
Metabolism in the small intestine to 1-acetyl-lysophosphatidylcholine.
The half-life is 32-66 hours. Elimination with feces.
Indications:
It is used to treat hepatosis (fatty liver degeneration), with alcoholic, toxic and medicinal liver damage. Used in the complex therapy for cirrhosis of the liver, viral hepatitis, psoriasis.
I.B15-B19.B17.1 Acute hepatitis C
I.B15-B19.B16 Acute hepatitis B
I.B15-B19.B15 Acute hepatitis A
I.B15-B19.B18.2 Chronic viral hepatitis C
I.B15-B19.B18.1 Chronic viral hepatitis B without delta-agent
XI.K70-K77.K70 Alcoholic liver disease
XI.K70-K77.K71 Toxic liver disease
XII.L40-L45.L40 Psoriasis
XI.K70-K77.K74 Fibrosis and cirrhosis of the liver
XI.K70-K77.K76.0 Fatty degeneration of the liver, not elsewhere classified
Contraindications:
Age to 12 years, pregnancy and lactation, antiphospholipid syndrome, individual intolerance.
Carefully:
Portal hypertension.
Pregnancy and lactation:
Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Inside with meals, 2 capsules 3 times a day. The course of treatment is 3-5 months.
The highest daily dose: 6 capsules.
The highest single dose: 2 capsules.
Side effects:
The cardiovascular system: transient arterial hypertension, peripheral edema.
Digestive system: dyspeptic phenomena.
Allergic reactions.
Overdose:
Cases of overdose are not described.
Treatment is symptomatic.
Interaction:
Clinically significant interactions are not described.
Special instructions:With a steady increase in blood pressure, titration of the dose or withdrawal of the drug is performed.